Skip to main content

Advertisement

Table 2 Comparison of remission and non-remission groups at 52 weeks

From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan

  Remission (n = 41) Non-remission (n = 21) P value
Age (years) 32.1 ± 10.5 34.9 ± 10.1 0.3201a
Gender (male) 75.6 % (31/41) 71.4 % (15/21) 0.7648c
Disease duration (months) 87.0 (0.0–480.0) 144.0 (0.0–336.0) 0.3964b
Disease duration < 2 years 36.6 % (15/41) 23.8 % (5/21) 0.3962c
Colonic type 4.9 % (2/41) 23.8 (5/21) *0.0387c
Surgery 61.0 % (25/41) 66.7 % (14/21) 0.7837c
Extra fistula 30.0 % (12/40) 42.9 % (9/21) 0.3980c
Intra fistula 7.5 % (3/40) 9.5 % (2/21) >0.9999c
Perianal disease 46.3 % (19/41) 52.4 % (11/21) 0.7895c
Smoking 17.6 % (6/34) 16.7 % (3/18) >0.9999c
Concomitant use    
 5-Aminosalicylates 87.8 % (36/41) 100 % (21/21) 0.1569c
 Steroids 9.8 % (4/41) 9.5 % (2/21) >0.9999c
 Immunomodulators 22.0 % (9/41) 28.6 % (6/21) 0.7548c
 Elemental diet 65.9 % (27/41) 57.1 % (12/21) 0.5829c
IFX experience    
 Experience with IFX 51.2 % (21/41) 57.1 % (12/21) 0.7895c
 Double dose 28.6 % (6/21) 41.7 % (5/12) 0.4713c
 Duration of IFX use (months) 19.5 (1.0–84.0) 10.0 (1.0–100) 0.7818b
 Reason of switch    0.5700d
  PNR 10.0 % (2/20) 0.0 % (0/12)  
  SNR 45.0 % (9/20) 50.0 % (6/12)  
  Intolerance 40.0 % (8/20) 50.0 % (6/12)  
  Other 5.0 % (1/20) 0.0 % (0/12)  
CDAI at baseline (points) 169.5 ± 76.8 215.4 ± 67.2 *0.0236a
CRP at baseline (mg/dL) 0.70 (0.00–6.86) 0.88 (0.02–6.34) 0.4436b
  1. Parametric variables are shown as mean ± standard deviation or median (range)
  2. IFX infliximab, PNR primary nonresponse, SNR secondary nonresponse, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein
  3. *P < 0.05
  4. aStudent’s t-test; bMann-Whitney U-test; cFisher’s exact test; dChi-square test